Lung cancer drug shows promise in Later-Line treatment
NCT ID NCT07400575
First seen Feb 12, 2026 · Last updated May 23, 2026 · Updated 16 times
Summary
This study examines the effectiveness and safety of anlotinib, a targeted therapy, for people with advanced non-small cell or small cell lung cancer who have already tried anlotinib and it stopped working. Researchers will review medical records from multiple hospitals to see if continuing anlotinib alone or with other drugs can help control the cancer. The goal is to provide real-world evidence for this cross-line treatment approach.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.